✦ LIBER ✦

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality

✍ Scribed by Ashwin Kashyap; John Wingard; Pablo Cagnoni; Roy Jones; Stephan Tarantolo; Wendy Hu; Karl Blume; Joyce Niland; Joycelynne M Palmer; William Vaughan; Hugo Fernandez; Richard Champlin; Stephen Forman; Borje S Andersson

Book ID: 117816236
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 136 KB
Volume: 8
Category: Article
ISSN: 1083-8791
DOI: 10.1053/bbmt.2002.v8.pm12374454

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once daily intravenous (IV) busulfan (Bu

Once daily intravenous (IV) busulfan (Bu) containing preparative regimens for hematopoietic stem cell transplantation (HSCT): Low incidence of Hepatic Veno-Occlusive Disease (HVOD) and improved early survival in a single center’s experience

✍ H. Benn; A. Amin; H.-C. Susan; D. Kramek; N. Janbay; D. Randhawa; R. Nath 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 63 KB